All Programs

Use the tool below to view all available AXISMedEd Activities

CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CME/CE Live Broadcast
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
February 28, 2025
12:00 PM - 01:00 PM EST
1.00 credit Learn more
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CE
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
0.25 credits
- Jorge E. Cortes, MD
0.25 credits
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
CME/CE
Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection
0.25 credits
- Mark Socinski, MD
0.25 credits
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
CME/CE
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
0.50 credits
- Sagar Lonial, MD, FACP
- Meghan Berkenstock, MD
- Saad Z. Usmani, MD, MBA, FACP
0.50 credits
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
CME/CE
Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
CME/CE
Community Practice Perspectives: Exploring Treatment Intensification with CDK4/6 Inhibitors in Adjuvant HR+, HER2−, High-Risk Early Breast Cancer
0.50 credits
- Adam Brufsky, MD, PhD
0.50 credits
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
CME/CE
Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting
0.50 credits
- Helena Yu, MD
0.50 credits
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
CME/CE
Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL
0.50 credits
- Matthew S. Davids, MD, MMSc
0.50 credits
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
CME/CE
Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer
0.50 credits
- Joshua E. Reuss, MD
0.50 credits
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CME/CE
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
0.50 credits
- Matthew Lunning, DO, FACP
0.50 credits
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
CME/CE
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
0.25 credits
- Sara M. Tolaney, MD, MPH
0.25 credits
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
CME/CE
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
1.00 credit
- Kathleen Moore, MD, MS, FASCO
1.00 credit
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
CME/CE
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
1.00 credit
- Kathleen Moore, MD, MS, FASCO
1.00 credit

All Programs

Popular

Title

Share on ReachMD